2021
DOI: 10.1186/s13036-021-00269-2
|View full text |Cite|
|
Sign up to set email alerts
|

Engineered hypoxia-responding Escherichia coli carrying cardiac peptide genes, suppresses tumor growth, angiogenesis and metastasis in vivo

Abstract: Development of engineered non-pathogenic bacteria, capable of expressing anti-cancer proteins under tumor-specific conditions, is an ideal approach for selectively eradicating proliferating cancer cells. Herein, using an engineered hypoxia responding nirB promoter, we developed an engineered Escherichia coli BW25133 strain capable of expressing cardiac peptides and GFP signaling protein under hypoxic condition for spatiotemporal targeting of mice mammary tumors. Following determination of the in vitro cytotoxi… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
4
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

3
5

Authors

Journals

citations
Cited by 12 publications
(4 citation statements)
references
References 67 publications
0
4
0
Order By: Relevance
“…This, together with lower ATP requirements (as explained above), may explain the greater formation of biomass and FbFP in strain PR1 under oxygen limitation. The performance of PR1 strain in oxygen‐limited regimes makes it an attractive host for the production of vaccines and antimicrobial peptides under microaerobic conditions, which can be preferred over aerobic regimes, to enhance the product activity (Abdolmohammadi Khiav & Zahmatkesh, 2021; Christmann et al, 2023; Samadi et al, 2021).…”
Section: Resultsmentioning
confidence: 99%
“…This, together with lower ATP requirements (as explained above), may explain the greater formation of biomass and FbFP in strain PR1 under oxygen limitation. The performance of PR1 strain in oxygen‐limited regimes makes it an attractive host for the production of vaccines and antimicrobial peptides under microaerobic conditions, which can be preferred over aerobic regimes, to enhance the product activity (Abdolmohammadi Khiav & Zahmatkesh, 2021; Christmann et al, 2023; Samadi et al, 2021).…”
Section: Resultsmentioning
confidence: 99%
“…One of the problems with using antibodies is their large size; thus, researchers are trying to increase the tumor permeability by replacing antibodies with smaller peptides and aptamers [143,207]. Using specific peptides instead of antibodies could solve this limitation (large size) and enhance the tumor permeability.…”
Section: Epcam and Novel Therapymentioning
confidence: 99%
“…186 Many molecules could activate apoptosis of cancer cells, which could be further investigated. 187 Aside from apoptosis induction, disruption of tumor angiogenesis is also promising in retarding tumor growth. Basic fibroblast growth factor (BFGF), as a compensative molecule of VEGF, can cause resistance to anti-VEGF therapy and is regarded as another potential antitumor target.…”
mentioning
confidence: 99%